Systems established for traditional pharmacokinetic (PK) and pharmacodynamic (PD) analyses were not designed to support complex clinical trials of new drugs in development. The incorporation of biomarkers into early drug trials has challenged leading companies to reprioritize innovation and drive quality sample management systems. As clinical development pipelines expand, companies should explore partnerships that will allow for scalability, enabling efficient and improved sample management.
Highlighting the importance of quality sample management in the development of immunotherapies
- Bridging the gap between research and clinical operations teams to design custom sample management processes
- Emphasizing the significance of real-time sample tracking to deliver high quality data
- Exploring new innovations and partnerships to enable efficient and improved sample management
- Reducing development timelines to bring effective immunotherapy to patients